$CNSP

CNS Pharmaceuticals, Inc. (CNSP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below under Item 5.07 of this Current Report, CNS Pharmaceuticals, Inc. (the “Company”) held its scheduled 2026

Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.

Fisher Michal purchased 2,000 shares of CNS Pharmaceuticals, Inc. (CNSP) at $5.00 on 2026-05-18.

CNS Pharmaceuticals (CNSP) reported Q2 2026 results with a basic and diluted loss of $0.37 per share, wider than the expected $0.24, and a net loss of $2.6M. The company said the per-share loss improved 94.2% year over year versus Q2 2025. Analysts’ consensus cited 4 buys, 1 hold, 0 sells.

CNS Pharmaceuticals (CNSP) filed an amended annual report (10-K/A) to update information

CNS Pharmaceuticals (NASDAQ: CNSP) is undergoing a strategic pivot, shifting its focus from solely glioblastoma to building an in-licensed pipeline in neurology and oncology. This change follows the Phase 2 trial failure of its legacy asset Berubicin to demonstrate superiority over lomustine in overall survival. The company faces a going concern risk, with cash flow projections indicating it can fund operations only into the third quarter of 2026, necessitating additional capital.

CNS Pharmaceuticals reported a net loss of $15.85 million for the year, primarily due to increased research and development spending for clinical programs. The company's operating loss totaled $15.99 million, with a loss per basic share of $35.75 based on 443,369 weighted average shares outstanding. They also raised equity in 2025 to fund operations and trials through mid-2026.

CNS Pharmaceuticals (CNSP) has appointed Lynne Kelley, MD, FACS, as its new Chief Medical Officer (CMO). Dr. Kelley previously served as CMO at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals, and Senseonics. This appointment follows recent restructuring in the company's financial leadership.